Enlivex Therapeutics Ltd. (ENLV) is a Biotechnology company in the Healthcare sector, currently trading at $0.80. It has a SharesGrow Score of 66/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ENLV = $470.92 (+58691.5% from the current price, the stock appears undervalued). Analyst consensus target is ENLV = $15 (+1772.7% upside).
Valuation: ENLV trades at a trailing Price-to-Earnings (P/E) of 0 (S&P 500 average ~25).
Net income is $1.2B, growing at +2794.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $641,000 against $1.9B equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 193.24 (strong liquidity). Debt-to-assets is 0%. Total assets: $2.3B.
Analyst outlook: 3 / 4 analysts rate ENLV as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 85/100 (Pass), Income ?/100 (Fail).
